


PCSK9 inhibitors attenuate atherosclerosis by promoting macrophage autophagy



Supplementary Figure 1. PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibition had no significant effects on the circulating lipid levels of ApoE^{-/-} mice. (A-D) Apolipoprotein E (ApoE)^{-/-} mice fed a high-fat diet (HFD) for 8 weeks were treated with saline or a PCSK9 inhibitor evolocumab for another 8 weeks. Quantification of the circulating levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein-cholesterol (LDL-C), and high-density lipoprotein-cholesterol (HDL-C) by enzymatic methods (n=8 mice per group). All data are presented as the mean \pm standard error of the mean (SEM).